Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Grit Lorenczewski"'
Autor:
Grit Lorenczewski, Sabine Stienen, Matthias Friedrich, Derk Jan A. de Groot, Frans V. Suurs, Elisabeth G.E. de Vries, Marjolijn N. Lub-de Hooge
Publikováno v:
Journal of Nuclear Medicine, 61(11), 1594-1601. SOC NUCLEAR MEDICINE INC
Bispecific T-cell engager (BiTE) molecules are designed to engage and activate cytotoxic T cells to kill tumor cells. Little is known about their biodistribution in immunocompetent settings. Methods: To explore their pharmacokinetics and the role of
Autor:
Frans V. Suurs, Matthias Friedrich, Julie M. Bailis, Elisabeth G.E. de Vries, Fei Lee, Derk-Jan A. de Groot, Marjolijn N. Lub-de Hooge, Sabine Stienen, Bert van der Vegt, Grit Lorenczewski
Publikováno v:
Journal of Nuclear Medicine, 62(5). SOC NUCLEAR MEDICINE INC
J Nucl Med
J Nucl Med
Bispecific T-cell engager (BiTE) molecules exert antitumor activity by binding one arm to CD3 on cytotoxic T cells and the other arm to a tumor-associated antigen. Methods: We generated a fully mouse cross-reactive mesothelin-targeted BiTE molecule t
Autor:
Elizabeth T. Andrews, Stephanie C. Casey, Mohammad Farhad Amani, Grit Lorenczewski, Mozhgan Farshbaf, Lisa Winkel, Matthias Klinger, John M. Harrold, Famke Aeffner, Ana Goyos, Matthias Friedrich, Tara Arvedson, Matthew G. Chun
Publikováno v:
Cancer Research. 82:6251-6251
Multiple myeloma (MM) is a cancer of the antibody-producing plasma cells (PC). MM is invariably fatal due to frequent disease relapse and/or treatment refractoriness, and therapies that provide deeper and more durable responses are needed. BiTE® (Bi
Autor:
Ines Ullrich, Oliver Thomas, Markus Muenz, Benno Rattel, Mercedesz Balazs, Julie M. Bailis, Joachim Wahl, Alexander Sternjak, Fei Lee, Grit Lorenczewski, Matthias Friedrich
Publikováno v:
Molecular cancer therapeutics. 20(5)
AMG 596 is a bispecific T-cell engager (BiTE) immuno-oncology therapy in clinical development for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor in adults with limited therapeutic options. AMG 596 is composed of two s
Autor:
Marjolijn N. Lub-de Hooge, Julie M. Bailis, Sabine Stienen, Derk Jan A. de Groot, Grit Lorenczewski, E.G.E. de Vries, Frans V. Suurs, Matthias Friedrich
Publikováno v:
Cancer Research. 80:2769-2769
BiTE® (bispecific T cell engager) immune therapy consists of two connected single-chain variable fragments, one targeting T-cells via CD3, and one targeting the tumor via a tumor-associated antigen. Given their short half-life, these molecules are a
Autor:
Grit Lorenczewski, Derk Jan A. de Groot, Elisabeth G.E. de Vries, Urszula M. Domanska, Marjolijn N. Lub-de Hooge, Matthias Friedrich, Frans V. Suurs, Sabine Stienen
Publikováno v:
Cancer Research. 79:1134-1134
BACKGROUND Bispecific T-cell engagers (BiTE®) harness the immune system against cancer. BiTE® antibody constructs are small proteins of ~53 kDa existing of two connected single-chain variable fragments. MuS110, a BiTE® with affinity for murine CD3
Autor:
Eva Vieser, Bernd Schlereth, Roman Kischel, Matthias G. Friedrich, Klaus Brischwein, Patrick A. Baeuerle, Maria Amann, Petra Lutterbuese, Peter Kufer, Grit Lorenczewski, Laetitia Petersen
Publikováno v:
Cancer Immunology, Immunotherapy. 58:95-109
MuS110 is a BiTE antibody bispecific for murine EpCAM (CD326) and murine CD3. A recent study has shown that microS110 has significant anti tumor activity at well-tolerated doses as low as 5 microg/kg in orthotopic breast and lung cancer models (Amann
Autor:
Bernd Schlereth, Sandrine Crommer, Antonio J. da Silva, Robert Hofmeister, Grit Lorenczewski, Mathias Locher, Laetitia Petersen, Klaus Brischwein, Patrick A. Baeuerle, Sandra Lippold, Petra Lutterbuese
Publikováno v:
Cancer Immunology, Immunotherapy. 56:459-468
An important mode of action shared by human IgG1 antibody therapies is antibody-dependent cellular cytotoxicity (ADCC). ADCC relies on the interaction of the antibody's Fc portion with Fc-gama receptors (FcgammaR) on immune effector cells. The anti-t
Autor:
Peter Kufer, Amartya Basu, Andreas Wolf, Mirnalini Sriskandarajah, Stefan Buziol, Susanne Mangold, Karen Yang, Inessa Hochheim, Larissa Parr, Tobias Raum, Poul Sørensen, Julia Hepp, Jörg Volkland, Sandra Bruckmaier, Petra Lutterbüse, Michael Molhoj, David Filpula, Markus Strasser, Christian Itin, Patrick A. Baeuerle, Silke Petsch, Grit Lorenczewski, Laetitia Petersen, Patrick Hoffmann, Eva-Maria Krinner, Ioana Schuster
Publikováno v:
Protein Engineering Design and Selection. 19:461-470
GM-CSF (granulocyte-macrophage colony stimulating factor) plays a central role in inflammatory processes. Treatment with antibodies neutralizing murine GM-CSF showed significant therapeutic effects in mouse models of inflammatory diseases. We constru
Autor:
Antonio J. da Silva, Petra Kleindienst, Roman Kischel, Sandra Lippold, Klaus Brischwein, Iduna Fichtner, Patrick A. Baeuerle, Bernd Schlereth, Mathias Locher, Ralf Lutterbüse, Grit Lorenczewski, Peter Kufer
Publikováno v:
Cancer Immunology, Immunotherapy. 55:785-796
Bispecific single-chain antibody constructs specific for human CD3 have been extensively studied for antitumor activity in human xenograft models using severe combined immunodeficient mice supplemented with human T cells. High efficacy at low effecto